Abstract：Objective To explore the role of peripheral blood eosinophils in the hormone therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 224 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to our hospital between January 2016 and October 2017 were divided into four groups according to the levels of peripheral blood eosinophils and the selection of hormone therapy:the hormone treatment group (group A) with elevated blood EOS, hormone treatment group with normal blood EOS (group B), non-hormone treatment group with elevated blood EOS (group C), and non-hormone treatment group with normal blood EOS (group D). Information about the gender, age, comorbidities, CAT scores, blood analysis, blood gas analysis, lung function, and nitric oxide breath test of these patients was collected. All the four groups were given oxygen, anti-inflammatory and antiasthmatic treatment,phlegm reduction and other general treatments, but Group A and group B additionally received hormone therapy. After one week, the results of blood analysis, FENO and CAT score of all these were reviewed. The length of hospital stay and rehospitalization rate of the four groups 3 months after discharge were recorded. Statistical analysis was conducted. Results There was no statistically significant difference in the general data, blood gas analysis, hemoglobin or lung function between the four groups. The average length of hospital stay was the shortest in group A and the rate of re-hospitalization 3 months after discharge was also the lowest, with statistically significant differences (P<0.05). Conclusions Peripheral blood eosinophils are of great importance in the hormone therapy for acute exacerbation of chronic obstructive pulmonary disease.
Kohei H, Carlos A,Camargo J. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD[J]. Respirology,2016, 21:761-764.
[5]
Pascoe S, Locantore N, Dransfield M T, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials[J]. Lancet Respir Med,2015,3(6):435-442.
Hasegawa K,Camargo, J R. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD [J]. Respirology, 2016. 21(4):761 - 764.
[8]
Panzner P, Lafitte J, Tsicopoulos A, et al. Marked upregulation of T lymphocytes and expression of interleukin-9 in bronchial biopsies from patients With chronic bronchitis with obstruction[J]. Chest,2003,124(5):1909-1915.
[9]
Riise G C, Ahlstedt S, Larsson S, et al. Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid[J]. Thorax,1995,50(4):360-365.
Bafadhel M, Greening N G, Harvey T C, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD[J]. Chest,2016,150(2) :320-328.
[12]
Cheng S L, Lin C H. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts[J]. Int J Chron Obstruct Pulmon Dis,2016, 21(11):2341-2348.
2020, Vol. 31 
